{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:53:45Z","timestamp":1790747625201,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ymgme.2020.10.006","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T03:28:37Z","timestamp":1602646117000},"page":"86-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Proteomics for the study of new biomarkers in Fabry disease: State of the art"],"prefix":"10.1016","volume":"132","author":[{"given":"Federica","family":"Rossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"L'Imperio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Svarstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena Maria","family":"Bolognesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvio","family":"Magni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Pagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pieruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2020.10.006_bb0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1750-1172-4-21","article-title":"Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring","volume":"4","author":"Hoffmann","year":"2009","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0010","first-page":"1","article-title":"Natural history of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Chapter 19.","author":"Mehta","year":"2006","journal-title":"Oxford Pharma Genesis"},{"key":"10.1016\/j.ymgme.2020.10.006_bb0015","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","article-title":"Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria","volume":"51","author":"T\u00f8ndel","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1651-2227.2005.tb02112.x","article-title":"Is globotriaosylceramide a useful biomarker in Fabry disease?","volume":"94","author":"Young","year":"2007","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0025","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10545-006-0484-8","article-title":"The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels","volume":"30","author":"Vedder","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0030","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.chemphyslip.2008.05.051","article-title":"Elevated globotriaosylsphingosine as a hallmark of Fabry disease","volume":"154","author":"Poorthuis","year":"2008","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.ymgme.2020.10.006_bb0035","doi-asserted-by":"crossref","DOI":"10.2215\/CJN.09480819","article-title":"The Changing Landscape of Fabry Disease","author":"Svarstad","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0040","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ymgme.2012.07.003","article-title":"Mutant \u03b1-galactosidase A with M296I does not cause elevation of the plasma globotriaosylsphingosine level","volume":"107","author":"Mitobe","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0045","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.cca.2010.07.038","article-title":"How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?","volume":"411","author":"Auray-Blais","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2020.10.006_bb0050","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10545-005-4415-x","article-title":"Monitoring enzyme replacement therapy in Fabry disease--role of urine globotriaosylceramide","volume":"28","author":"Whitfield","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0055","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.3390\/ijms16023537","article-title":"Proteomic challenges: sample preparation techniques for microgram-quantity protein analysis from biological samples","volume":"16","author":"Feist","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0060","series-title":"Proteomics in Practice: A Guide to Successful Experimental Design","author":"Westermeier","year":"2008"},{"key":"10.1016\/j.ymgme.2020.10.006_bb0065","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s13205-011-0037-1","article-title":"Current methods in structural proteomics and its applications in biological sciences","volume":"2","author":"Manjasetty","year":"2012","journal-title":"3 Biotech."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0070","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/35015709","article-title":"Proteomics to study genes and genomes","volume":"405","author":"Pandey","year":"2000","journal-title":"Nature."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0075","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.201700180","article-title":"What is targeted proteomics? A concise revision of targeted acquisition and targeted data analysis in mass spectrometry","volume":"17","author":"Borr\u00e0s","year":"2017","journal-title":"Proteomics"},{"key":"10.1016\/j.ymgme.2020.10.006_bb0080","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1039\/C4MB00707G","article-title":"Early markers of Fabry disease revealed by proteomics","volume":"11","author":"Matafora","year":"2015","journal-title":"Mol. BioSyst."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0085","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2144\/000112823","article-title":"Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE): advances and perspectives","volume":"44","author":"Issaq","year":"2008","journal-title":"Biotechniques."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0090","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1002\/pmic.200800298","article-title":"Difference gel electrophoresis","volume":"8","author":"Timms","year":"2008","journal-title":"Proteomics."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0095","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jchromb.2008.10.048","article-title":"Technical, bioinformatical and statistical aspects of liquid chromatography-mass spectrometry (LC-MS) and capillary electrophoresis-mass spectrometry (CE-MS) based clinical proteomics: a critical assessment","volume":"877","author":"Dakna","year":"2009","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0100","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1126\/science.2675315","article-title":"Electrospray ionization for mass spectrometry of large biomolecules","volume":"246","author":"Fenn","year":"1989","journal-title":"Science."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0105","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1021\/ac00171a028","article-title":"Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons","volume":"60","author":"Karas","year":"1988","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0110","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1080\/05704920902717872","article-title":"Mass spectrometry, review of the basics: electrospray, MALDI, and commonly used mass Analyzers","volume":"44","author":"El-Aneed","year":"2009","journal-title":"Appl. Spectrosc. Rev."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0115","first-page":"20150382","article-title":"Quantitative mass spectrometry: an overview, philosophical transactions of the Royal Society a: mathematical","volume":"374","author":"Urban","year":"2016","journal-title":"Phys. Eng. Sci."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0120","doi-asserted-by":"crossref","DOI":"10.1002\/prca.201700074","article-title":"Clinical proteomics for precision medicine: the bladder cancer case","volume":"12","author":"Latosinska","year":"2018","journal-title":"Proteomics Clin. Appl."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18122588","article-title":"Matrix-assisted laser desorption\/ionisation mass spectrometry imaging in the study of gastric cancer: a mini review","volume":"18","author":"Smith","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0130","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jfda.2019.01.001","article-title":"Current status of MALDI-TOF mass spectrometry in clinical microbiology","volume":"27","author":"Hou","year":"2019","journal-title":"J. Food Drug Anal."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0135","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jasms.2006.09.013","article-title":"MALDI TOF\/TOF tandem mass spectrometry as a new tool for amino acid analysis","volume":"18","author":"Gogichaeva","year":"2007","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0140","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1080\/14789450.2018.1505510","article-title":"Applications of MALDI-TOF mass spectrometry in clinical proteomics","volume":"15","author":"Greco","year":"2018","journal-title":"Expert Rev. Proteomics."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0145","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.semnephrol.2007.09.002","article-title":"Direct tissue analysis by matrix-assisted laser desorption ionization mass spectrometry: application to kidney biology","volume":"27","author":"Herring","year":"2007","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0150","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1039\/C4MB00716F","article-title":"A MALDI-mass spectrometry imaging method applicable to different formalin-fixed paraffin-embedded human tissues","volume":"11","author":"De Sio","year":"2015","journal-title":"Mol. BioSyst."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0155","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/his.12337","article-title":"MALDI imaging mass spectrometry in glomerulonephritis: feasibility study","volume":"64","author":"Mainini","year":"2014","journal-title":"Histopathology."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0160","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/pmic.201500411","article-title":"\u03b1-1-Antitrypsin detected by MALDI imaging in the study of glomerulonephritis: Its relevance in chronic kidney disease progression","volume":"16","author":"Smith","year":"2016","journal-title":"Proteomics"},{"key":"10.1016\/j.ymgme.2020.10.006_bb0165","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000505187","article-title":"Detecting proteomic indicators to distinguish diabetic nephropathy from hypertensive Nephrosclerosis by integrating matrix-assisted laser desorption\/ionization mass spectrometry imaging with high-mass accuracy mass spectrometry","volume":"45","author":"Smith","year":"2020","journal-title":"Kidney Blood Press. Res."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0170","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.bbapap.2016.11.013","article-title":"The putative role of MALDI-MSI in the study of membranous nephropathy","volume":"1865","author":"Smith","year":"2017","journal-title":"Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics"},{"key":"10.1016\/j.ymgme.2020.10.006_bb0175","article-title":"MALDI-MSI pilot study highlights glomerular deposits of macrophage migration inhibitory factor as a possible Indicator of response to therapy in membranous nephropathy","volume":"13","author":"L\u2019Imperio","year":"2019","journal-title":"Proteomics Clin. Appl."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0180","doi-asserted-by":"crossref","DOI":"10.1002\/prca.201800016","article-title":"High spatial resolution MALDI-MS imaging in the study of membranous nephropathy","volume":"13","author":"Smith","year":"2019","journal-title":"Proteomics Clin. Appl."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/diseases5020015","article-title":"Biomarkers and imaging findings of anderson-fabry disease-what we know now","volume":"5","author":"Beir\u00e3o","year":"2017","journal-title":"Diseases"},{"key":"10.1016\/j.ymgme.2020.10.006_bb0190","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1159\/000488121","article-title":"Fabry nephropathy: An evidence-based narrative review","volume":"43","author":"Del Pino","year":"2018","journal-title":"Kidney Blood Press. Res."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0195","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/ncpneph0806","article-title":"Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults","volume":"4","author":"Ortiz","year":"2008","journal-title":"Nat. Clin. Pract. Nephrol."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0200","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000369309","article-title":"Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria","volume":"129","author":"T\u00f8ndel","year":"2015","journal-title":"Nephron."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0205","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3109\/0886022X.2010.516859","article-title":"Study of urinary proteomes in Anderson-Fabry disease","volume":"32","author":"Vojtov\u00e1","year":"2010","journal-title":"Ren. Fail."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0210","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/ki.2011.134","article-title":"The rediscovery of uromodulin (Tamm-Horsfall protein): from tubulointerstitial nephropathy to chronic kidney disease","volume":"80","author":"Rampoldi","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0215","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1021\/pr301200e","article-title":"The identification of new biomarkers for identifying and monitoring kidney disease and their translation into a rapid mass spectrometry-based test: evidence of presymptomatic kidney disease in pediatric Fabry and type-I diabetic patients","volume":"12","author":"Manwaring","year":"2013","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0220","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/jmedgenet-2019-106030","article-title":"Rapid, proteomic urine assay for monitoring progressive organ disease in Fabry disease","volume":"57","author":"Doykov","year":"2020","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020534","article-title":"A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy","volume":"6","author":"Kistler","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2020.10.006_bb0230","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1073\/pnas.0611315104","article-title":"Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify biological abnormalities","volume":"104","author":"Moore","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0235","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/jmedgenet-2017-104704","article-title":"Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy","volume":"54","author":"Heo","year":"2017","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0240","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1039\/c3mb25402j","article-title":"Alteration of proteomic profiles in PBMC isolated from patients with Fabry disease: preliminary findings","volume":"9","author":"Cigna","year":"2013","journal-title":"Mol. BioSyst."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0245","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ejhf.230","article-title":"Gender-specific plasma proteomic biomarkers in patients with Anderson-Fabry disease","volume":"17","author":"Hollander","year":"2015","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0250","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-29240-w","article-title":"Urine-derived cells: a promising diagnostic tool in Fabry disease patients","volume":"8","author":"Slaats","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0255","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.ymgme.2018.12.269","article-title":"Proteomic profiling of engineered human immortalized podocyte cell model of Fabry disease","volume":"126","author":"Neto","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0260","article-title":"MALDI imaging in Fabry nephropathy: a multicenter study","author":"L\u2019Imperio","year":"2019","journal-title":"J. Nephrol."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0265","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/ndt\/gfq306","article-title":"Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy","volume":"26","author":"Sanchez-Ni\u00f1o","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0270","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1159\/000345465","article-title":"Possible pathogenetic relationship between Fabry disease and renal cell carcinoma","volume":"36","author":"Pagni","year":"2012","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.ymgme.2020.10.006_bb0275","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/prca.201500075","article-title":"Proteomics and glomerulonephritis: a complementary approach in renal pathology for the identification of chronic kidney disease related markers","volume":"10","author":"L\u2019Imperio","year":"2016","journal-title":"PROTEOMICS - Clin. Appl."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719220302067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719220302067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:29:35Z","timestamp":1761089375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719220302067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1096719220302067"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2020.10.006","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proteomics for the study of new biomarkers in Fabry disease: State of the art","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2020.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}